| Accession Number: | 0000899243-23-012347 |
| Date: | 2023-04-28 |
| Issuer: | AMBRX BIOPHARMA INC. (AMAM) |
| Original Submission Date: |
AROMANDO ANDREW
C/O AMBRX BIOPHARMA INC.,
10975 TORREY PINES ROAD
LA JOLLA, CA 92037
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY) | 1.38 | 2023-04-28 | deemed execution date | A | 2,600,000 (a) | 2033-04-28 | ordinary shares 2,600,000 | $1.38 | 2,600,000 | direct |
| ID | footnote |
|---|---|
| f1 | the options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the issuer's american depositary shares ("adss"). |
| f2 | grant awarded as an inducement grant in connection with the reporting person's appointment as chief operating officer of the issuer. |
| f3 | twenty-five percent of the ordinary shares subject to the option vested on april 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date. |
| f4 | the ordinary shares of the issuer may be represented by adss. each ads represents seven ordinary shares of the issuer. |
